European drug-makers benefit from those high prices in the US, too. But anyway, I’ve heard that only 11-14% of new drugs are therapeutically important. The rest compete with pre-existing treatments, which I believe is how generic forms bring costs down. I’m ok with universities doing this; bringing costs down does save the lives of poor people.